Physician profile
Michael D Barry
NPI 1497718597
$10,119.41
in general payments reported to CMS, 2019-2025
31 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,194 · 2020: $417 · 2021: $1,001 · 2022: $3,365 · 2023: $627 · 2024: $962 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,868.65 | 2021-2022 | |
| Medtronic Vascular, INC. | $2,658.45 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $1,071.05 | 2020-2025 | Optimizer |
| Abbott Laboratories | $772.94 | 2019-2025 | Gallant, Proclaim, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $712.14 | 2019-2025 | |
| Philips North America LLC | $355.74 | 2019-2023 | |
| Angiodynamics, INC. | $335.77 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Boston Scientific Corporation | $287.10 | 2022-2025 | Synergy, General - Atherectomy, General - Stents |
| Janssen Pharmaceuticals, INC | $136.87 | 2019-2023 | Xarelto |
| Nevro Corp. | $129.84 | 2024 | Senza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.76 | 2019-2024 | Lifevest |
| Pfizer INC. | $77.32 | 2019-2022 | |
| Bardy Diagnostics, INC. | $64.34 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.11 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.57 | 2019-2025 | Eliquis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.85 | 2020-2022 | |
| Amgen INC. | $44.22 | 2023-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $41.76 | 2022-2024 | Opsumit |
| Abiomed | $36.21 | 2020 | |
| Lilly USA, LLC | $35.00 | 2025 | Zepbound, Mounjaro |
| Atricure, INC. | $33.50 | 2024 | |
| Amarin Pharma, INC. | $26.96 | 2020 | |
| Lundbeck LLC | $25.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.27 | 2020-2021 | |
| Edwards Lifesciences Corporation | $24.02 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.55 | 2022 | |
| Sirtex Medical INC | $18.79 | 2024 | Sir-Spheres Microspheres |
| Cagent Vascular INC | $15.19 | 2024 | Serrantor |
| Inspire Medical Systems, INC. | $15.19 | 2025 | Inspire |
| Preventice Services, LLC | $14.46 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.